

FOR IMMEDIATE RELEASE

**SPECTRUM DYNAMICS AND CYCLOPHARMA
SIGN STRATEGIC AGREEMENT FOR DISTRIBUTION IN EUROPE**

Orangeburg NY, Jan 26th, 2009 – Spectrum Dynamics and Cyclopharma announced today that the two companies have signed a strategic agreement to establish Cyclopharma as the exclusive distributor for Spectrum-Dynamics' D-SPECT Cardiac Scanner System throughout Europe. The D-SPECT Cardiac Scanner with proprietary BroadView imaging technology represents a breakthrough in almost every component of nuclear imaging workflow and diagnostics.

Under the terms of the agreement, Cyclopharma will be responsible for distribution and service support of the D-SPECT Cardiac Scanner throughout Europe. "We are confident that the superior performance of the D-SPECT coupled with Cyclopharma's distribution and support network will enhance the adoption of the D-SPECT technology throughout Europe. Spectrum-Dynamics is committed to providing its customers with exceptional products and services. We are confident that the partnership with Cyclopharma will broaden Spectrum's market reach and will result in a significant increase in world-wide market share." states Jim Haisler, CEO of Spectrum-Dynamics.

About Cyclopharma:

Cyclopharma is a leading French radiopharmaceutical company specializing in production and distribution of radiopharmaceuticals (chiefly ¹⁸FDG) and cold kits in the field of nuclear medicine. Cyclopharma has recently developed an engineering subsidiary for production of short half-life isotopes by means of a cyclotron that has been designed by the company. In addition, they are a major distributor of technegas and cold kits in France. Cyclopharma is very excited about this new technology which they believe will lead the new generation of technology in the field of SPECT imaging. Bernard Salin, PhD, Cyclopharma's CEO: "It is a revolution in nuclear medicine. The gain in sensitivity provided by the DSPECT technology provides the foundation for reduction of radiation doses to the patient, and is extremely important in today's environment with increased awareness to radiation exposure and technetium supply shortages frequently occurring." Serge Askienazy, MD, PhD, Medical and research director "Fast acquisition with high spatial resolution and increased patient comfort which is now available by DSPECT is a true breakthrough in the field of SPECT imaging."

About Spectrum-Dynamics:

Spectrum-Dynamics, with offices in New York and California and research/production facilities in Caesarea Israel, is a pioneering medical device company focused on personalized molecular imaging and applications. Spectrum Dynamics will revolutionize the practice of nuclear cardiology, and eventually all nuclear medicine applications, by

dramatically enhancing workflow and providing new clinical applications not possible with conventional technology.

Additional information can be found at www.spectrum-dynamics.com.

Statement

This press release may contain forward-looking statements about Spectrum Dynamics, including projections about our business and the nuclear medicine market. Those forward-looking statements are not guarantees of future performance and actual results could differ.

-END-

For further information please contact:

Miri Tal, Vice President of Global Operations & Head of European desk

Tel: (972) 73-737-4545, e-mail: MiriT@spectrum-dynamics.com